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Abstract
The primary association of both type 2 diabetes mellitus (T2DM) 
and fragility fractures with age has become cause for concern in the 
developed world, with T2DM now considered an independent risk 
factor for an increased risk of fragility fracture. The increased sus-
ceptibility to fragility fracture associated with T2DM has wide rang-
ing and increasing socioeconomic, morbidity and mortality effects. 
As the incidence of T2DM increases, understanding the mechanisms 
behind why T2DM is a causative risk factor to decreased bone health 
is an important step. These may be split into two broad categories: 
those that involve an increased risk of falling, and those mechanisms 
that make fragility fracture after falling more likely due to detrimen-
tal changes to bone strength. The latter is not definitively understood 
making diagnosis in T2DM populations difficult. Current diagnostic 
methods do not sufficiently account for the unique endocrinological 
effects of T2DM on bone. New markers for identifying fragility frac-
ture risk in patients with T2DM are required to overcome the para-
doxical increase in bone mineral density (BMD) in these populations, 
and the shortcomings of predictive algorithms and dual energy X-ray 
absorptiometry (DXA) in identifying fracture risk in T2DM popula-
tions. Earlier identification of patients with T2DM who are at risk of 
fragility fracture is important, as these patients are not as responsive 
to current preventative medical interventions as those without T2DM, 
although there are also adoptive lifestyle changes that can help.
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Introduction
Osteoporosis is a chronic progressive bone disease character-
ized by a loss of bone mineral density (BMD) and structural 
integrity resulting in fragility fractures. It is currently clinically 
diagnosed using dual energy X-ray absorptiometry (DXA) as 
a loss of BMD of more than 2.5 times less than the mean peak 
bone density for gender (i.e. a -2.5 T-score) [1]. The resulting 
increased risk of “fragility” fractures, occurring from a stand-
ing height fall or less, has wide ranging and increasing socio-
economic, morbidity and mortality effects [2]. Indeed, there 
are approximately 300,000 fragility fractures in the UK each 
year, and with the growing elderly population, fragility frac-
tures are predicted to cost the UK healthcare economy up to 
£2.2 billion by 2025 [2].
Type 2 diabetes mellitus (T2DM), although considered a 
disease of glucose regulation, is associated with wide-rang-
ing derangement of metabolic and vascular homeostasis [3]. 
Worldwide approximately 382 million people have diabetes, 
3.2 million of whom are in the UK, of which 90% have type 
2 [4, 5]. This number is anticipated to rise to 592 million by 
2035, with 22% of the rise happening in Europe [4]. The prev-
alence of T2DM increases dramatically in ageing populations 
with around two-thirds of cases in those aged over 60 [5].
People with T2DM are classically thought of as having an 
increased body mass index (BMI) and an associated increase 
in BMD, and are therefore anticipated to be protected from os-
teoporosis. Paradoxically, however, type 2 diabetes is associat-
ed with an increased risk of fragility fracture [6]. For example, 
there is a reported relative risk ratio of 1.7 for hip fracture in 
people with T2DM compared to those without [7]. Similarly, 
the odds ratio for vertebral fracture in people with T2DM ver-
sus those without is 1.9 for females and 4.7 for men, even after 
adjusting for age, BMI and lumbar BMD [8]. Some of this may 
be accounted for by the increased risk of falling in those with 
diabetes due to, for example, hypoglycemia, peripheral neu-
ropathy, nocturia, retinopathy or impaired vascular homeosta-
sis leading to postural hypotension [9]. Similarly, obesity and 
a sedentary lifestyle can affect balance, gait and co-ordination. 
Any combination of these can lead to an increased falls risk [3, 
10, 11]. However, even in studies that controlled for fall fre-
quency, T2DM remained independently associated with higher 
fragility fracture risk [6]. There is also a positive correlation 
with the risk of fragility fracture in patients relative to the time 
they have had T2DM, suggesting a link in the mechanism of 
these two diseases [8, 12]. Further, people with T2DM also 
demonstrate slower bone healing and increased risk of non-
union with non-displaced fractures taking up to 87% longer to 
heal [10], suggesting T2DM may be associated or even pre-
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cipitate an independent bone pathology.
Mechanisms
Evidence is compelling that people with T2DM have an in-
creased risk of fragility fracture [3, 9]. However, the mecha-
nisms behind this risk have not been elucidated. As a popula-
tion, people with T2DM have no change or even an increase 
in BMD despite the evidenced increase risk of fragility frac-
ture even after adjustment for patient age and the higher body 
weight typically seen in people with T2DM [3, 6, 12]. This 
increased BMD may, in part, be due to the anabolic effect of 
extra mechanical loading on bone associated with the distribu-
tion of obesity seen in T2DM, compounded by the relative in-
crease in circulating hormonal factors known to stimulate bone 
deposition such as insulin, parathormone, estrogen, leptin and 
adiponectin in patients with T2DM [3, 12].
BMD, however, is only one measure of bone strength. At-
tenuated bone architecture, even in the presence of unchanged 
BMD, has been proposed as an explanation for the increased 
risk of fragility fractures in people with T2DM. Normal tra-
becular bone is structured as a 3D scaffolding of internal rods 
or plates that are oriented along the lines of stress. The spaces 
around this trabecular structure of the axial skeleton are also 
the primary repository of red bone marrow, meaning trabecular 
bone is in close proximity with the marrow-derived cells that 
participate in bone turnover. As such the integrity of trabecu-
lar bone is also dependent on its microvascular blood supply. 
Disruption of trabecular continuity by trabecular perforation 
results in reduced connectivity of the trabecular bone structure, 
and thereby weakens the scaffold on which the bone is based 
without necessarily reducing bone mass [13].
The need to quantify this has led to new ways of meas-
uring bone architectural integrity independent of BMD as a 
predictor for fragility fracture, such as trabecular bone scor-
ing (TBS) [14]. At the same BMD, lower bone strength (as 
measured by TBS) has been demonstrated in those with hip 
fractures and T2DM [6], as has increased porosity within the 
trabecular bone of the distal radius [15]. This suggests poorer 
structural integrity of bone may play a role in the increased rate 
of fragility fractures in patients with T2DM. This is thought to 
be linked with reduced bone activity, as evidenced by lower 
levels of biochemical measures of bone turnover and parathor-
mone in patients with T2DM [16]. There are several proposed 
mechanisms for this reduced bone activity.
Microvascular angiopathies
In 1980, poor vascular supply to bone was first proposed to 
explain a higher prevalence of hip fracture in patients with 
diabetes mellitus [17]. In 1983, Demmler et al also noted a 
decreased density of arterial capillaries in osteoporotic bone 
and proposed a “vascular component to the pathogenesis of os-
teoporosis” [18]. In 1997, Vogt et al found that losses in BMD 
in the lower limbs were correlated with poor peripheral blood 
supply [19]. In animal models, diabetic microangiopathy has 
been demonstrated to affect homeostasis in bone marrow [20].
Further associations between micro- and macrovascular 
disease and increased fragility fracture risk have since been 
reported [21, 22], suggesting that reduced tissue (including 
bone) perfusion may be associated with increased fracture risk. 
Of course, microvascular disease also results in diabetic com-
plications such as peripheral neuropathy, associated with an 
increased risk of falls. However, even when stratifying for fall 
frequency, macrovascular and microvascular diabetic compli-
cations can be indirectly associated with increased fragility 
fracture risk. This is particularly enhanced in the presence of 
multiple complications (for example coronary artery disease, 
retinopathy, etc.), suggesting either a contributory component 
of microcirculatory dysfunction or shared risk factors [6].
Hyperglycemia
An increase in the glycation processes associated with hy-
perglycemia can lead to the generation of an increased con-
centration of advanced glycation end-products (AGEs) such 
as pentosidine in bone. Interactions between AGEs and AGE 
receptors (R-AGEs) have been found to adversely affect bone 
turnover and healing [23]. Increased AGEs have been linked 
with reduced bone strength as they can increase apoptosis in 
osteoblasts [3] and at the same time increase osteoclastic activ-
ity [8]. Increased AGEs have also been demonstrated to affect 
the structural cross-linking of collagen resulting in a more brit-
tle scaffolding structural arrangement in bone with increased 
stiffness and poorer structural integrity [12, 24]. Thus it is not 
surprising that chronic hyperglycemia alters bone turnover and 
puts patients at further risk of fragility fracture [11]. Chronic 
hyperglycemia can also trigger poor bone health due to the 
associated glycosuria. This can lead to hypercalciuria which 
leads to lower calcium levels, affecting bone quality [23].
Oxidative stress may be another potential cause of reduced 
bone turnover, and thus bone strength. This can be caused by 
T2DM-induced increases in AGEs, and insufficiency or resist-
ance of insulin [25]. Recent work has also suggested glycemic 
variability is an independent trigger of oxidative stress [26]. 
This may account for the association seen between some anti-
hyperglycemic agents such as insulin, which promote rapid 
glycemic shifts, and the increased risk of fractures. The posi-
tive effects of anti-hyperglycemic drugs (such as metformin) 
on reducing fragility fractures by reducing AGEs support this 
link between hyperglycemia and increased fracture risk [11, 
12]. As such, there is potential for investigation into other al-
ternative AGE reducing drugs such as raloxifene, teriparatide 
and vitamin B6 to be trialled specifically for the treatment of 
osteoporosis in T2DM [24].
Osteocalcin levels
There is a clinically proven relationship between glucose-
fat metabolism and bone metabolism. This two-way link is 
predominately controlled by osteocalcin, which is a protein 
secreted by osteoblasts to encourage bone growth, but has 
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also been found to increase glucose metabolism by increas-
ing insulin secretion and sensitivity. Insulin also can decrease 
osteoprotegerin expression, which has the effect of reducing 
osteoclast activity [12]. Thus reduced osteocalcin can reduce 
glucose metabolism as well as bone turnover via reducing os-
teoblast and osteoclast activity [8]. Increased levels of AGEs 
have also been linked with lower levels of osteocalcin produc-
tion [3].
Medicines for the management of T2DM
Treatment of T2DM with thiazolidinediones (an insulin sensi-
tizer), such as rosiglitazone and pioglitazone, has been linked 
with reduced bone turnover and unacceptable increases in frac-
ture risk and short-term reductions in BMD and is currently 
not recommended for patients at risk of fragility fracture [11]. 
Use of loop diuretics for hypertension secondary to T2DM has 
shown to increase fracture risk by increasing renal calcium ex-
cretion. Thiazide diuretics are thus preferred in those at frac-
ture risk since these conversely promote renal calcium absorp-
tion [11]. Insulin use is linked to an increase in fracture risk; 
however, it is unclear whether there is a causal link between 
insulin use, whether that be by suppression of osteocalcin, by 
glycemic variability or by other mechanisms and fracture risk, 
or whether this is simply confounded by the duration or sever-
ity of disease in those who take it [6].
Other associations
People with T2DM have been demonstrated to have an altered 
metabolism of vitamin D (with reduced serum concentrations) 
and attenuated amylin levels, both of which have been as-
sociated with poorer bone mineralization, bone turnover and 
bone strength [3, 11, 27]. Conversely, treatment with amylin 




The identification of those with T2DM at risk of fragility frac-
tures is a cause of considerable interest. The challenge in di-
agnosis lies in that fragility fracture risk does not seem to cor-
relate with bone density but rather bone quality [6, 8]. Current 
guidelines from the National Institute of Health and Care Ex-
cellence (NICE) for predicting the risk of fragility fracture rec-
ommend the use of predictive tools such as FRAX and QFrac-
ture in the first instance [2]. FRAX and QFracture are based 
on many of the patient’s clinical factors such as age, BMI, past 
history of fracture, family history of fragility fracture, co-mor-
bidities such as rheumatoid arthritis, smoking, alcohol intake, 
and medications. These are taken into consideration using an 
algorithm to give a predictive risk of fragility fracture within 
the next 10 years [2]. These predictive algorithms, however, 
underestimate fracture risk for patients with T2DM. Despite 
matching FRAX scores, patients with T2DM are more likely 
to subsequently fracture than those without diabetes [10, 11, 
28].
According to NICE guidelines, if the predicted risk of fra-
gility fracture is considered high enough to warrant potential 
preventative intervention then a measurement of BMD is indi-
cated [2]. The gold standard modality for this is DXA with T-
scores representing BMD relative to mean peak bone mass for 
the population [1]. However as BMD may be normal or even 
increased in people with T2DM, BMD is considered a poor 
predictor of fracture risk in T2DM populations [3]. DXA is 
also prone to false readings due to aortic calcification, sclerotic 
osteoarthritis or increased lipid content in bone, all of which 
have an increased prevalence in T2DM [10, 29].
The current gold standard for the measurement of bone 
structure is high resolution peripheral quantitative CT (HR-
QCT). Unfortunately, in the clinical arena, this is limited by 
radiation exposure, and the cost of investigation, and is there-
fore relatively rarely used [11]. TBS provides an alternative 
measurement of bone architecture using DXA scan images. 
Using pixel-by-pixel analysis of DXA scans of the lumbar 
spine, TBS provides an analogue of trabecular bone structure 
that has been demonstrated to predict fracture risk indepen-
dently of BMD [30, 31]. However, this has been demonstrated 
to have a higher precision error in an obese population [32].
Potential alternative approaches: measurement of bone 
perfusion
T2DM is a recognized precipitant of a very distinct vascu-
lopathy. Given the very clear associations between micro- and 
macrovascular disease in people with T2DM and an increased 
risk of fragility fracture, and the highly vascular nature of the 
trabecular bone, it would be reasonable to propose that the 
vasculopathy affecting every other system in the body could 
also play a role in the pathogenesis of the more brittle, normal 
density bones of those with T2DM. Confirming the association 
between adverse bone architecture and the microvascular per-
fusion of bone could enable development of protocols explor-
ing the benefit of targeting bone microcirculatory function, us-
ing existing therapies, in order to improve diabetic bone health 
and reduce fragility fracture risk. In addition, if impaired bone 
perfusion was proven to be linked with impaired systemic per-
fusion complications of T2DM, then these could be used as 
surrogate markers for increased risk of fragility fracture. How-
ever, measuring blood perfusion of bone is difficult. Current 
in vivo methods using positron emission tomography (PET) 
or magnetic resonance imaging (MRI) imaging protocols are 
invasive, expensive, have limited access, and do not allow 
regular repeated measurements [33, 34]. Further, oxygen satu-
ration and therefore consumption is not measured, only gross 
perfusion.
Potential alternative approaches: diagnostic biomarkers
The use of surrogate markers linked with AGEs is currently 
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being investigated as a potential indicator of bone quality [8]. 
Pentosidine is an AGE that accumulates with ageing, acceler-
ated by hyperglycemia, in various tissues including bone. Its 
accumulation in bone has been demonstrated to be greater in 
patients with femoral neck fractures than age matched controls 
suggesting it may be a potential marker for diabetic bone dis-
ease. Serum and urine pentosidine is representative of pento-
sidine in bone and is therefore a potentially viable surrogate 
marker for predicting bone strength independent of BMD [8].
Serum insulin-like growth factor 1 (IGF-1) and serum total 
adiponectin are also other potential predictive markers of bone 
metabolism [11]. IGF-1 can increase insulin sensitivity and 
also increases bone formation and turnover [27]. Adiponectin 
is secreted by fat tissue and bone marrow and enhances os-
teoblastic activity, thus it also has a role to play in boosting 
osteocalcin levels and thus insulin sensitivity and bone me-
tabolism [8]. These potential surrogate markers are yet to be 
clinically adopted as they are still unproven as predictors of 
fragility fracture risk in T2DM populations.
Treatment
The key element to the treatment of fragility fractures is its 
prevention. In order to prevent these fragility fractures early 
recognition of an increased fracture risk is essential. As T2DM 
is an independent risk factor for fragility fracture, independent 
of T-score or BMD, it would appear this is a suitable rationale 
for a low threshold to treat any person with T2DM. Current 
recommendations suggest treatment should be initiates at a T-
score of between -1 and -1.5, rather than the recommended 
-2.5 for those without diabetes [8].
Treatment for osteoporosis in people with T2DM, how-
ever, is not a straightforward process. Treatment can focus on 
an avoidance of diabetic drugs that reduce bone health, and 
improved glycemic control to minimize metabolic changes 
[11]. Other easily adopted lifestyle changes can also help re-
duce fragility fracture risk. These involve decreasing the risk 
of falls and good management of T2DM including early visual 
assessment, regular weight bearing exercise to improve mus-
cle strength and balance, specific measures to decrease the 
damage from falls (such as hip protectors), and education on 
vitamin D and calcium intake (including supplements) [3].
Conventional osteoporosis treatment strategies rely on ad-
dressing reduced BMD loss. There are two current routes to 
treating osteoporosis with medications, anti-resorptive medi-
cations (such as bisphosphonates, calcitonin and selective es-
trogen receptor modulators (SERMs)) and anabolic bone form-
ing medications that make use of parathyroid hormone [23].
Despite being widely accepted as first line therapy, bis-
phosphonates have not demonstrated any clear benefit on the 
effects on fracture likelihood in T2DM [10]. Simply putting 
a strategy based on increasing BMD does not benefit people 
who already have a normal or even high BMD. Other problems 
with bisphosphonate treatment include the relatively small risk 
of potential side effects such as atypical femoral fractures and 
osteonecrosis of the jaw (with T2DM being a risk factor). Poor 
patient compliance can also be an issue, as bisphosphonates 
need to be taken on an empty stomach during a period of fast-
ing for effective absorption [23]. Calcitonin can be used as an 
alternative to bisphosphonates as it suppresses osteoclast bone 
resorption, but is also linked with raising blood sugar levels. 
SERMs have been shown to not affect insulin sensitivity and 
are more effective than HRT at preventing osteoporotic frac-
tures in post-menopausal women, but also have potential side 
effects such as hot flushes and increased deep vein thrombosis 
risk [23]. Use of parathyroid hormone has been demonstrated 
to stimulate new bone growth and increase bone mass and may 
also benefit fracture healing. Their role in diabetes is uncertain, 
although forms such as teripartide may have additional benefit 
by reducing AGE levels [10]. Other medications that reduce 
AGE levels in patients with T2DM may be preferred such as 
vitamin B6, and the anti-resorptive SERM raloxifene [24].
Future areas of research include the anti-hyperglycemic 
agents affecting the incretin system such as the anabolic gluca-
gon-like peptide 1 (GLP-1) and the anti-resorptive dipeptidyl 
peptidase-4 (DPP-4) inhibitors. These have shown early po-
tential in T2DM treatment for improving glycemic control but 
also having an anabolic effect on bone health (which could 
perhaps be enhanced by concurrent thiazolidinedione use), al-
though the mechanisms behind this are not fully understood 
[35, 36]. Thiamine derivatives have also been suggested as a 
potential solution to reverse bone mineral reductions in pa-
tients with T2DM [20]. Research on osteocalcin treatment is 
also warranted as it encourages and regulates bone turnover 
whilst also improving insulin sensitivity [10]. Denosumab, a 
relatively new treatment, is a human monoclonal antibody that 
can inhibit the maturation of osteoclasts, thus reducing bone 
resorption. It has potential benefits over bisphosphonates as it 
is easily delivered and can be used in cases of impaired renal 
function, however has been associated with an increased inci-
dence of cellulitis, reduced immunity and osteonecrosis of the 
jaw [37].
Conclusion
In conclusion, there is clearly a strong case for reducing the 
incidence of fragility fractures in elderly populations. As the 
incidence of T2DM increases with age, understanding the 
mechanisms behind why T2DM is a causative risk factor to 
decreased bone health is an important step. Current diagnostic 
methods do not sufficiently account for the unique endocrino-
logical effects of T2DM on bone. New markers for identifying 
fracture risk in patients with T2DM are required to overcome 
the paradoxical increase in BMD in these populations, and the 
shortcomings of predictive algorithms and DXA in predicting 
fragility fracture risk in T2DM populations. A greater under-
standing of the nature of the pathology that leads to diabetic 
bone disease is required. Earlier identification of at risk people 
with T2DM is essential to reduce the risk of fragility fractures, 
as these patients are not as responsive to current medical inter-
ventions as those without T2DM.
Key statements
1) The incidence of T2DM continues to increase in the ageing 
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population.
2) T2DM is an independent risk factor for osteoporotic 
low energy “fragility fracture”.
3) It is not definitively understood how T2DM changes 
bone metabolism to increase the risk of osteoporotic low en-
ergy “fragility fracture”.
4) Current clinical diagnostic pathways do not sufficiently 
account for the unique endocrinological effects of T2DM on 
bone health.
5) Earlier identification of patients with T2DM who are at 
risk of fragility fracture is important as these patients are not as 
responsive to current preventative medical treatments as those 
without diabetes.
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